CIRM is accelerating stem cell therapies to patients with unmet medical needs

Accelerating Results

CIRM funds promising projects at any stage of research, providing them with the money they need when they need it — getting projects going within 120 days of applying.

- CIRM is funding nine projects approved for clinical trials in disease areas including cancer, heart disease, HIV and blood disorders. Several more therapies are expected to join that list soon.
- In addition, eight more clinical trials are underway using therapies developed from early work CIRM funded.
- CIRM funding has already resulted in almost 2,000 articles in scientific journals, advancing knowledge about all aspects of stem cell research.
- Research to date has proved that every kind of stem cell — adult, embryonic, reprogrammed (iPS) and cancer — holds potential for yielding results in treating dozens of life-threatening or life-impairing conditions.

With Partnerships

CIRM works as part of the project team, providing guidance and support from staff and outside experts, to increase the chances the project will be successful.

- CIRM devotes significant internal resources and leverages its vast network of world-class experts to advance the best research projects in the field.
- The partnership approach accelerates projects and increases the likelihood of success.
- The stem cell agency has created an environment across California that strongly supports both public and private sector research into life-saving and life-improving therapies.
- CIRM’s $271 million in major facilities grants helped attract an additional $543 million in funds from private donors and institutions.
- CIRM has turned California into a global leader in stem cell research. We have created partnerships with governments and organizations in 14 countries, one U.S. state, and four foundations leveraging the best scientific minds in the world.

Hand-in-hand with Patients

CIRM involves patient representatives at every stage of the process and as participants in the Clinical Advisory Panels that are part of the team once it has been funded.

- Each project is partnered with a project-specific advisory panel that includes at least one patient advisor with first hand experience of the specific condition.
- The patient advisors provide input, recommendations and the appropriate sense of urgency.
- Ten members of CIRM’s 29-member Board are patient advocates who participate in the review of grant applications and vote on final funding decisions.
- CIRM provides many learning opportunities for patients through its web site and social media and will provide speakers for public events upon request, email info@cirm.ca.gov.
Background

CIRM, California’s stem cell agency, was created by Proposition 71, a ballot measure passed by 59 percent of California voters in November 2004. The Institute is authorized to award $3 billion in state bond funds to advance stem cell research in California.

| Founded: 2004 |
| Employees: 52 employees |

Our Impact

Grants Awarded: As of January 2015, CIRM had awarded 688 research and facility grants to more than 70 California institutions, totaling more than $2 billion, with more than $1.3 billion already dispersed to those projects.

Active programs As of January 2015 CIRM had 80 active programs working with $627 million in funding

Clinical trials Nine clinical trials funded by CIRM have been approved as have another eight using therapies developed with CIRM funding

CIRM’s economic impact CIRM’s grants are estimated to generate 2.3 dollars in economic activity in the state for every dollar from CIRM.

CIRM’s first $1.6 billion in grants has generating $286 billion in new tax revenue for California

CIRM has been notified of more than 180 inventions from funded projects,

How We Work

Solicit high quality projects. CIRM invites teams with high quality projects at any stage of the research cycle, from early discovery to clinical, to submit applications when their projects are ready to be taken to the next level.

Independent outside reviewers. A team of independent scientific and business experts, from outside California, reviews the applications and determines which are the most promising. Our governing Board then votes, based on the review group’s recommendations, which ones to fund.

Focus on unmet medical needs CIRM seeks out projects that will benefit patients with significant unmet medical needs.

Leadership

Jonathan Thomas
ICOC board Chair

Art Torres
ICOC Vice Chair

C. Randall Mills, Ph.D.
CIRM President & CEO

Email Updates: cirm.ca.gov/about-cirm/newsletter-signup
Facebook Updates: facebook.com/CaliforniaInstituteForRegenerativeMedicine
YouTube: youtube.com/cirmtv
Twitter Updates: twitter.com/CIRMnews
Flickr Images: flickr.com/photos/cirm
Research Blog: blog.cirm.ca.gov
RSS Feeds: cirm.ca.gov/RSS_Feeds